Kestra Medical Technologies, Ltd. Research and Development Expense
Kestra Medical Technologies, Ltd. (KMTS) reported Research and Development Expense of $6.80 million for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-09-14
- Kestra Medical Technologies, Ltd. research and development expense for the quarter ending 2026-07-31 was $6.80M, a 69.86% increase year-over-year.
- Kestra Medical Technologies, Ltd. research and development expense for the quarter ending 2026-04-30 was $5.63M, a 4.60% increase year-over-year.
- Kestra Medical Technologies, Ltd. research and development expense for the quarter ending 2026-01-31 was $4.97M, a 48.29% increase year-over-year.
- Kestra Medical Technologies, Ltd. research and development expense for the quarter ending 2025-10-31 was $4.88M, a 39.01% increase year-over-year.
- Kestra Medical Technologies, Ltd. research and development expense for fiscal 2026 was $19.48M, a 24.48% increase from fiscal 2025.
- Kestra Medical Technologies, Ltd. research and development expense for fiscal 2025 was $15.65M, a 1.05% increase from fiscal 2024.
- Kestra Medical Technologies, Ltd. research and development expense for fiscal 2024 was $15.49M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-07-31 | $6.80M 10-Q · filed 2026-09-14 | $12.43M derived: sum of 2 quarters · filed 2026-09-14 | $17.40M derived: sum of 3 quarters · filed 2026-09-14 | $22.28M derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $5.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $10.61M derived: sum of 2 quarters · filed 2026-07-14 | $15.48M derived: sum of 3 quarters · filed 2026-07-14 | $19.48M 10-K · filed 2026-07-14 |
| 2026-01-31 | $4.97M 10-Q · filed 2026-03-17 | $9.85M derived: sum of 2 quarters · filed 2026-03-17 | $13.85M 10-Q · filed 2026-03-17 | $19.24M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $4.88M 10-Q · filed 2025-12-11 | $8.88M 10-Q · filed 2025-12-11 | $14.27M derived: sum of 3 quarters · filed 2026-09-14 | $17.62M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $4.00M 10-Q · filed 2026-09-14 | $9.39M derived: sum of 2 quarters · filed 2026-09-14 | $12.74M derived: sum of 3 quarters · filed 2026-09-14 | $16.25M derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-14 | $8.74M derived: sum of 2 quarters · filed 2026-07-14 | $12.25M derived: sum of 3 quarters · filed 2026-07-14 | $15.65M 10-K · filed 2026-07-14 |
| 2025-01-31 | $3.35M 10-Q · filed 2026-03-17 | $6.86M derived: sum of 2 quarters · filed 2026-03-17 | $10.27M 10-Q · filed 2026-03-17 | |
| 2024-10-31 | $3.51M 10-Q · filed 2025-12-11 | $6.91M 10-Q · filed 2025-12-11 | ||
| 2024-07-31 | $3.40M 10-Q · filed 2025-09-12 | |||
| 2024-04-30 | $15.49M 10-K · filed 2025-07-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |
| Beta Bionics, Inc. (BBNX) | United States | $0.979B | -9.66 |